Agenda
• 3:00-3:30 PM Networking & Registration
• 3:30-5:00 PM Financing Panel
• 5:00-5:30 PM Angelsoft™ and NIH Database Introduction
• 5:30-6:30 PM Networking Reception

Although VC's are a traditional source of funds, there are many opportunities for financing that can get your company to where you need it to be. You just need to know the right people.

Join our panel to hear from private wealthy individuals, government granting agencies, foundations, angels and VCs who have opportunities for you to fund your company.

Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception and Ipod raffle.

Speakers
• Kurt A. Henry, MD, Biological Defense Research Directorate, US Naval Medical Research Center, DOD
• Ted McCluskey, MD, PhD, Board Member, Sand Hill Angels; & CMO, Aviir, Inc. Click Here for Bio»
• JC Simbana, Director, SVB Capital Click Here for Bio»
• Adam S. Bristol, PhD, Portfolio Manager & Investment Researcher, Biotechnology Value Fund, L.P. Click Here for Bio»
• Erez Levy, Managing Director, International Group, TriplePoint Capital Click Here for Bio»
• Guy Miller MD, PhD, Chairman, CEO, Edison Pharmaceuticals Click Here for Bio»
• Sohini Chowdhury, Associate Director, Research Programs, The Michael J. Fox Foundation for Parkinson's Research Click Here for Bio»
• Lead Facilitator: Gregory W. Heibel, Partner, Corporate Group, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LLP Click Here for Bio»


Speakers Bios

Ted McCluskey, MD, PhD, Board Member, Sand Hill Angels; & CMO, Aviir, Inc.
Ted McCluskey MD/PhD, is a co-chair of membership at Sand Hill Angels. He is currently at Scios, Inc. (a Johnson & Johnson company) in Mountain View where he works on the clinical development of Scios' lead biopharmaceutical, Natrecor. In addition, in his more than three years at Scios, Ted has overseen clinical development of VEGF in pre-eclampsia, participated in cardiovascular business development assessments and worked on internal strategy and leadership projects.
Prior to Scios, Ted was at Genentech for 8 years, overseeing clinical research on cardiovascular applications for TNKase, Bosentan, CathFlo Activase and most recently for the recently approved anti-angiogenic ophthalmic agent Lucentis. He led the clinical development for the cardiovascular application of VEGF (vascular endothelial growth factor) by direct intra-coronary injection. He has had extensive experience in both in-licensing and out-licensing projects. While at Genentech, he received additional training in Finance, Marketing and Management (Berkeley) and in Leadership and Strategy at an executive program at Harvard Business School.
Ted was trained as an interventional cardiologist (Cleveland Clinic) and served for several years on the faculty of the University of Cincinnati. Prior molecular biology and clinical cardiology training were at UCSF. His medicine residency was at Washington University in St. Louis as were his MD and PhD (Pharmacology). His undergraduate degree was in chemistry (with research honors) from Stanford.

JC Simbana, Director, SVB Capital
JC Simbana is a director with SVB Capital and leads the Life Science Practice of its Venture Exchange program. Venture Exchange serves as a platform to provide quality referrals to venture firms and assist emerging companies in raising capital through strategic introductions to the right investors for seed, Series A and follow on investments. Simbana has more than ten years of experience in financial services, with extensive experience in venture banking and equity research.
Prior to joining SVB Capital in 2008, Simbana led Square 1 Bank's Life Science Practice in Northern California, where he focused on strengthening relationships with select venture capital firms and providing banking and debt financing solutions to venture-backed companies.
Simbana began his venture banking career with Comerica's technology and life science Division. Prior to commercial banking, he spent five years as an equity analyst for Moors & Cabot, Inc.'s Technology Research Group. The combination of his experience as a venture banker and institutional equity analyst give Simbana a deep understanding of a client's needs from seed-stage to IPO.
He holds a bachelor's degree in business administration from Colorado State University, and is active in several life science organizations, including Astia's Life Science Committee, American Heart Association and the American Diabetes Association Leaders Forum.

Adam S. Bristol, PhD, Portfolio Manager & Investment Researcher, Biotechnology Value Fund, L.P.
Dr. Bristol is a portfolio manager and investment researcher at Biotechnology Value Fund, a dedicated life science investment fund based in San Francisco, CA. He has served as a start-up mentor for NIH's Commercialization Assistance Program through LARTA and for UC-Davis's Environmental Health Entrepreneurship Academy. He obtained his PhD in cellular and systems neuroscience from Yale University and did his postdoctoral training at Stanford University's School of Medicine.
The Biotechnology Value Fund (BVF) is a dedicated life science private investment fund. Started in 1993, BVF currently has over $600M in assets. Our investments focus on seed-stage, pre-clinical companies developing breakthrough drugs and drug discovery technologies that have the potential to do substantial social good. Our experience in corporate development allows us to work closely with companies and help them reach preclinical milestones and maximize growth potential with an emphasis on attracting non-dilutive capital. Our current family of investments includes Acumen Pharmaceuticals, Airmid, Biotica, CFD Therapeutics, Keel Pharmaceuticals, Mendel Biotechnologies, and Viriome.

Erez Levy, Managing Director, International Group, TriplePoint Capital
Erez Levy is a Managing Director at TriplePoint Capital, a leading global specialty finance company with an unsurpassed capacity to transact loans and leases with leading high-growth companies throughout their lifespan.
Prior to joining TriplePoint Capital Erez served as a senior investment banker at JPMorgan’s technology group in San Francisco, where he worked with many leading technology and high growth companies, raising capital and providing advice on mergers and acquisitions.
Prior to JPMorgan, Erez was at Hambrecht & Quist (H&Q), a leading technology and life-sciences investment bank where he worked with many of the firms clients. At H&Q, Erez also led several of the firm’s investments in leading technology and high-growth companies.
In addition, Erez was instrumental in building both H&Q’s and JPMorgan’s international technology investment banking practices.

Guy Miller MD, PhD, Chairman, CEO, Edison Pharmaceuticals
Guy Miller, MD, PhD, is the Chairman and Chief Executive Officer of Edison Pharmaceuticals. He holds a clinical faculty appointment at Stanford University School of Medicine/PAVAMC, in medical-surgical critical care and is an Adjunct Professor, University of North Carolina, School of Public Health. Prior to Edison, he founded Galileo Pharmaceuticals, and was its Chairman and CEO from 1995-2005. Dr. Miller completed a surgical internship at the University of Chicago and residency and fellowship in anesthesiology & critical care medicine at Johns Hopkins, where he was an Assistant Professor until 1995.
Edison has obtained substantial non-dilutive peer-reviewed grant support to advance both its pre-clinical and clinical initiatives from foundations including the Muscular Dystrophy Association, Friedreich's Ataxia Research Alliance, and Seek A Miracle. The company closed Series A Preferred Stock Offering in November 2005, and recently announced a Series B Financing led by Mr. Carl Berg, Berg & Berg Enterprises, LLC. New investors include John W. Marriott, III, President and CEO of JWM, LP, and JWM Family Enterprises.

Sohini Chowdhury, Associate Director, Research Programs, The Michael J. Fox Foundation for Parkinson's Research
Sohini Chowdhury is the point person for The Michael J. Fox Foundation for Parkinson's Research on all industry activity. Ms. Chowdhury joined the Foundation after spending five years at the World Economic Forum in Geneva, Switzerland. As the Senior Community Manager of the Forum's Technology Pioneers program, she was responsible for annually selecting and integrating innovative biotech, energy and IT technology companies into Forum activities. Ms. Chowdhury also worked directly for the Forum's CEO, acting as his liaison with key Forum stakeholders and overseeing several in-house projects. Ms. Chowdhury graduated with an MA from Georgetown University, and holds a BA in International Studies from Vassar College.
The path from research discovery to the creation of a new treatment is often an extremely long one. The average time for the development of a new central nervous system treatment is currently 13 years. The Michael J. Fox Foundation is helping to speed up drug development for PD with innovative strategies that identify roadblocks along the therapeutic development pipeline. By sharing the risk of drug development with academic and industry researchers alike, we hope to increase the movement of new treatments into the clinic.
The Michael J. Fox Foundation's unique value-add lies not in any single investment, but in pursuing multiple promising initiatives at once. As a private funder, with a comprehensive view of the field and proactive management of the grants in our portfolio, MJFF is ideally positioned to identify opportunities and create synergies all along the continuum from basic to clinical research. We do this in service of one principal goal: systematically shepherding basic discoveries and translational advances toward meaningful clinical outcomes. All potential MJFF investments are evaluated against their promise to return meaningful progress in critical areas of the therapeutics development pipeline.

Lead Facilitator: Gregory W. Heibel, Partner, Corporate Group, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LLP
Greg Heibel, a partner in the Silicon Valley office, is a member of the Emerging Companies practice group, which advises emerging and public technology companies, venture capital firms and other technology investors. Mr. Heibel’s practice includes the formation, financing and general corporate counseling of rapidly growing technology companies; the representation of venture capital firms and other investors in private and public offerings, as well as other complex transactions related to high growth companies. Mr. Heibel has completed hundreds of venture capital financings, mergers, acquisitions and licensing transactions for clients in the networking, wireless, Internet, software, life sciences and consumer industries. Additionally, Mr. Heibel has represented numerous Nasdaq listed companies in their public offering, mergers and acquisitions and ongoing corporate governance needs, including Foundry Networks, Virage Networks, Adeza, Laserscope, Intellisync and Preview Systems.